☆ 3.8 Article

Crohn’s and Colitis Canada’s 2021 Impact of COVID-19 and Inflammatory Bowel Disease in Canada: Risk Factors and Medications

Journal of the Canadian Association of Gastroenterology (2021)

Related references

Note: Only part of the references are listed.

Article Gastroenterology & Hepatology

Effect of IBD medications on COVID-19 outcomes: results from an international registry

Ryan C. Ungaro et al.

Summary: Combination therapy and thiopurines may be associated with an increased risk of severe COVID-19, while no significant differences were observed when comparing classes of biologicals. These findings warrant confirmation in large population-based cohorts.

GUT (2021)

Add to Collection

Article Gastroenterology & Hepatology

Prevalence and Outcomes of COVID-19 Among Patients With Inflammatory Bowel Disease-A Danish Prospective Population-based Cohort Study

Mohamed Attauabi et al.

Summary: Patients with immune-mediated inflammatory diseases, including IBD, were less susceptible to COVID-19 compared to patients without such diseases, and use of immunosuppressive therapies or disease activity of IBD did not affect the disease course of COVID-19.

JOURNAL OF CROHNS & COLITIS (2021)

Add to Collection

Article Gastroenterology & Hepatology

Characteristics and Outcomes of IBD Patients with COVID-19 on Tofacitinib Therapy in the SECURE-IBD Registry

Manasi Agrawal et al.

INFLAMMATORY BOWEL DISEASES (2021)

Add to Collection

Review Gastroenterology & Hepatology

Risk and outcomes of coronavirus disease in patients with inflammatory bowel disease: A systematic review and meta-analysis

Anupam Kumar Singh et al.

Summary: The risk of SARS-CoV-2 infection in patients with inflammatory bowel disease is comparable to the general population, with worse outcomes in ulcerative colitis, patients on steroids or 5-aminosalicylates, but better outcomes with biological agents.

UNITED EUROPEAN GASTROENTEROLOGY JOURNAL (2021)

Add to Collection

Article Gastroenterology & Hepatology

Inflammatory bowel disease and risk of severe COVID-19: A nationwide population-based cohort study in Sweden

Jonas F. Ludvigsson et al.

Summary: While individuals with IBD were more likely to be admitted to hospital for COVID-19 than the general population, the risk of severe COVID-19 was not higher.

UNITED EUROPEAN GASTROENTEROLOGY JOURNAL (2021)

Add to Collection

Article Gastroenterology & Hepatology

Fr493 DISEASE ACTIVITY IS ASSOCIATED WITH COVID-19 OUTCOMES IN IBD PATIENTS WITH EFFECT MODIFICATION BY AGE

Amanda Ricciuto et al.

GASTROENTEROLOGY (2021)

Add to Collection

Article Gastroenterology & Hepatology

The Impact of Vedolizumab on COVID-19 Outcomes Among Adult IBD Patients in the SECURE-IBD Registry

Manasi Agrawal et al.

Summary: The study found that COVID-19 outcomes in IBD patients on VDZ were comparable to those on all other therapies. Compared to anti-TNF monotherapy, VDZ monotherapy was more likely to result in hospitalization, but less likely to result in severe COVID-19. Overall, VDZ appears to be safe in IBD patients with COVID-19.

JOURNAL OF CROHNS & COLITIS (2021)

Add to Collection

Article Dermatology

Tumor necrosis factor inhibitors are associated with a decreased risk of COVID-19-associated hospitalization in patients with psoriasis-A population-based cohort study

Khalaf Kridin et al.

Summary: This study found that patients with psoriasis treated with tumor necrosis factor inhibitors (TNFi) have a comparable risk of COVID-19 infection but a lower risk of hospitalization compared to methotrexate and ustekinumab. There was no significant difference in COVID-19 mortality among the different treatment groups. TNFi may be a viable option for patients with moderate-to-severe psoriasis during the pandemic.

DERMATOLOGIC THERAPY (2021)

Add to Collection

Article Gastroenterology & Hepatology

Risk of common infections in people with inflammatory bowel disease in primary care: a population-based cohort study

Peter M. Irving et al.

Summary: The study evaluated the risk of common infections in individuals with inflammatory bowel disease compared with matched controls in a UK primary care population. It found that people with IBD are more likely to present with a wide range of common infections, with ulcerative colitis and Crohn's disease patients having higher infection risks. Treatment with oral glucocorticoid therapy, immunotherapies, and biologic therapy was associated with increased infection risk in IBD patients.

BMJ OPEN GASTROENTEROLOGY (2021)

Add to Collection

Article Gastroenterology & Hepatology

Uneventful course in IBD patients during SARS-CoV-2 outbreak in northern Italy

Lorenzo Norsa et al.

GASTROENTEROLOGY (2020)

Add to Collection

Article Gastroenterology & Hepatology

Corticosteroids, But Not TNF Antagonists, Are Associated With Adverse COVID-19 Outcomes in Patients With Inflammatory Bowel Diseases: Results From an International Registry

Erica J. Brenner et al.

GASTROENTEROLOGY (2020)

Add to Collection

Article Gastroenterology & Hepatology

Management of Patients with Crohn’s Disease and Ulcerative Colitis During the COVID-19 Pandemic: Results of an International Meeting

David T. Rubin et al.

GASTROENTEROLOGY (2020)

Add to Collection

Editorial Material Gastroenterology & Hepatology

Impact of Anti-Tumor Necrosis Factor and Thiopurine Medications on the Development of COVID-19 in Patients With Inflammatory Bowel Disease: A Nationwide Veterans Administration Cohort Study

Nabeel Khan et al.

GASTROENTEROLOGY (2020)

Add to Collection

Editorial Material Gastroenterology & Hepatology

Implications of COVID-19 for patients with pre-existing digestive diseases

Ren Mao et al.

LANCET GASTROENTEROLOGY & HEPATOLOGY (2020)

Add to Collection

Letter Gastroenterology & Hepatology

Data Visualization in the Era of COVID-19: An Interactive Map of the SECURE-IBD Registry

Joseph W. Windsor et al.

AMERICAN JOURNAL OF GASTROENTEROLOGY (2020)

Add to Collection

Article Multidisciplinary Sciences

Factors associated with COVID-19-related death using OpenSAFELY

Elizabeth J. Williamson et al.

NATURE (2020)

Add to Collection

Review Gastroenterology & Hepatology

Effectiveness and safety of Ustekinumab for Crohn's disease; systematic review and pooled analysis of real-world evidence

Tal Engel et al.

DIGESTIVE AND LIVER DISEASE (2019)

Add to Collection

Article Gastroenterology & Hepatology

Risk of Serious and Opportunistic Infections Associated With Treatment of Inflammatory Bowel Diseases

Julien Kirchgesner et al.

GASTROENTEROLOGY (2018)

Add to Collection

Article Gastroenterology & Hepatology

Effectiveness and Safety of lmmunomodulators With Anti-Tumor Necrosis Factor Therapy in Crohn's Disease

Mark T. Osterman et al.

CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2015)

Add to Collection

Article Gastroenterology & Hepatology

Oral Corticosteroids and the Risk of Serious Infections in Patients With Elderly-Onset Inflammatory Bowel Diseases

Paul Brassard et al.

AMERICAN JOURNAL OF GASTROENTEROLOGY (2014)

Add to Collection

Article Gastroenterology & Hepatology

Serious Infection and Mortality in Patients With Crohn's Disease: More Than 5 Years of Follow-Up in the TREAT™ Registry

Gary R. Lichtenstein et al.

AMERICAN JOURNAL OF GASTROENTEROLOGY (2012)

Add to Collection

Article Gastroenterology & Hepatology

Risk factors for opportunistic infections in patients with inflammatory bowel disease

Murat Toruner et al.

GASTROENTEROLOGY (2008)

Add to Collection

© Peeref 2019-2024. All rights reserved.